Tipifarnib
- Generic Name
- Tipifarnib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H22Cl2N4O
- CAS Number
- 192185-72-1
- Unique Ingredient Identifier
- MAT637500A
- Background
Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.
- Indication
Investigated for use/treatment in colorectal cancer, leukemia (myeloid), pancreatic cancer, and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Tipifarnib in Treating Patients With Recurrent Bladder Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- University Health Network, Toronto
- Registration Number
- NCT00047216
- Locations
- 🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇨🇦St. Joseph's Hospital, Hamilton, Ontario, Canada
Tipifarnib in Treating Patients With Advanced Hematologic Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00005967
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
- Conditions
- Interventions
- First Posted Date
- 2001-07-23
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 62
- Registration Number
- NCT00021541
- Locations
- 🇺🇸
The Children's Hospital, Dana-Farber Cancer Institute, Boston, MA (M1034), Boston, Massachusetts, United States
🇺🇸Children's Memorial Hospital, Chicago, IL (M1484), Chicago, Illinois, United States
🇺🇸Childrens Hospital of Philadelphia, PA (M1257), Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.